Skip to content

menu

Pharma in Brief logo
HomeAboutContact
Search
Close
Pharmaceuticals and life sciencesIntellectual propertyLife sciences and healthcare
View topics Archives
Subscribe

Pharma in Brief

British Columbia signs first funding agreement under the national rare disease strategy

Photo of Sarah PenningtonPhoto of Christopher A. GuerreiroPhoto of Kristin Wall
By Sarah Pennington, Christopher A. Guerreiro & Kristin Wall on August 18, 2024

On July 23, 2024, the Governments of Canada and British Columbia (BC) announced the execution of a National Strategy for Drugs for Rare Diseases (DRD) Agreement. This is the first DRD agreement reached since the…

Subscribe to Pharma in Brief

Subscribe to this publication

Drug pricing: PMPRB launches next phase of the Guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on June 28, 2024

The Patented Medicine Prices Review Board (PMPRB) has released a new Discussion Guide for consultation on new price review Guidelines. The Discussion Guide outlines a proposed new price review process and requests stakeholder feedback on several specific topics…

CADTH to Transform into Canada’s Drug Agency

Photo of Sarah PenningtonPhoto of Christopher A. GuerreiroPhoto of Kristin Wall
By Sarah Pennington, Christopher A. Guerreiro & Kristin Wall on May 6, 2024

Canada’s Drug and Health Technology Agency (CADTH) has announced that, as of May 1, 2024, its new operating name will be Canada’s Drug Agency / l’Agence des médicaments du Canada (CDA-AMC). The official launch will occur…

Pharmacare Update: Budget 2024

Photo of Sarah PenningtonPhoto of Kristin WallPhoto of Paul Jorgensen
By Sarah Pennington, Kristin Wall & Paul Jorgensen on April 16, 2024

Canada’s federal 2024 budget has set aside $1.5 billion over five years to launch pharmacare, which will introduce national universal drug coverage to Canada.

Background

As we reported, on February 29, 2024, the federal government tabled Bill C-64…

Drug pricing: PMPRB announces next steps in Guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on April 14, 2024

The Patented Medicine Prices Review Board (PMPRB) has announced new details regarding the progress of its consultation on new price review Guidelines.

Phase 2: Discussion Guide

The next phase of the PMPRB’s consultation will begin in summer 2024…

Drug price negotiations: pCPA Temporary Access Process launched

Photo of Sarah PenningtonPhoto of Kristin WallPhoto of Paul Jorgensen
By Sarah Pennington, Kristin Wall & Paul Jorgensen on April 10, 2024

The pan-Canadian Pharmaceutical Alliance (pCPA) has launched its Temporary Access Process (pTAP) to facilitate early market access to new drugs that were assessed under the time-limited reimbursement recommendation (TLR) pathway at the Canada Drug…

National Pharmacare bill tabled

Photo of Sarah PenningtonPhoto of Kristin WallPhoto of Paul Jorgensen
By Sarah Pennington, Kristin Wall & Paul Jorgensen on March 1, 2024

On February 29, 2024, the federal government tabled Bill C-64, An Act respecting pharmacare (the Pharmacare Act). The Pharmacare Act outlines the “foundational principles” for the first phase of a national universal drug coverage plan in Canada. The legislation…

Federal Court of Appeal clarifies law on patentability of methods of medical treatment

Photo of Christopher A. GuerreiroPhoto of Pardeep HeirPhoto of Anna Wilkinson
By Christopher A. Guerreiro, Pardeep Heir & Anna Wilkinson on February 29, 2024

The Federal Court of Appeal (FCA) has held that in order to determine whether a patent claims an unpatentable method of medical treatment (MMT), it is necessary to determine whether the use of the invention requires…

Health Canada disclosing more information on pending generic drug submissions

Photo of Sarah PenningtonPhoto of Kristin WallPhoto of Paul Jorgensen
By Sarah Pennington, Kristin Wall & Paul Jorgensen on February 25, 2024

On February 23, 2024, Health Canada published a Notice advising that it was making its review process for generic drug submissions more transparent.  Specifically, for generic drug submissions accepted into review on or after April 1, 2024, Health Canada will…

Drug pricing: PMPRB releases “What We Learned” Report on guidelines consultation

Photo of Kristin WallPhoto of Christopher A. Guerreiro
By Kristin Wall & Christopher A. Guerreiro on February 16, 2024

The Patented Medicine Prices Review Board (PMPRB or Board) has released a “What We Learned” Report (the Report), marking the next step along the path to new Guidelines. The Report was prepared by Phoenix Strategic Perspectives Inc.…

Post navigation

 Newer PostsOlder Posts 
The latest from our blog network
Norton Rose Blog Network
Global Regulation Tomorrow

FCA publishes good and poor practice in relation to improving applications for authorisation in the asset management sector

April 10, 2026
Global Regulation Tomorrow

FCA Primary Market Bulletin 62

April 10, 2026
Global Regulation Tomorrow

European Commission adopts Delegated Regulations on disclosures and trading under MAR

April 10, 2026
Global Regulation Tomorrow

FCA publishes findings in relation to firms’ customer due diligence processes and controls

April 10, 2026
Global Regulation Tomorrow

EIOPA publishes technical specification for small and non-complex undertakings and groups criteria under Solvency II

April 10, 2026
Global Regulation Tomorrow

EBA consults on revised Guidelines on limits on exposures to shadow banking entities under the Capital Requirements Regulation

April 10, 2026
Global Regulation Tomorrow

Refreshed Foreign Financial Service Provider regime

April 9, 2026
Global Regulation Tomorrow

Podcast | Split the Difference: Episode 19 – Prediction Markets and Event Contracts

April 8, 2026
Data Protection Report

Navigating AI compliance with HIPAA essentials

April 7, 2026
View the Norton Rose blog network

Pharma in Brief

LinkedIn Twitter Facebook RSS YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date with legal and regulatory developments affecting the pharmaceutical industry. Pharma in Brief provides timely updates with a focus on the key take-away you need to know.

Read more

Topics

Archives

Copyright © 2026, Norton Rose Fulbright LLP. All rights reserved.